Change in Number of Shares and Votes in Immunicum AB (publ) After Completed Directed Issue 28 December 2018 Read more R
Immunicum AB (publ) Publishes the Outcome in the Share Issues and Raises SEK 351M 13 December 2018 Read more R
Immunicum AB (publ) Publishes Prospectus in Connection with Rights Issue and Directed Issue 23 November 2018 Read more R
Immunicum AB (publ) Announces Collaboration with Merck KGaA, Darmstadt, Germany, and Pfizer to Evaluate Ilixadencel in Combination with Avelumab in Multi-Indication Phase Ib/II Study 16 November 2018 Read more R
Report from Extraordinary General Meeting of Immunicum AB (publ) on 8 November 2018 8 November 2018 Read more R
Immunicum AB (publ) Announces Upcoming Investor Events in October and November 22 October 2018 Read more
Immunicum AB (publ) Presents Preclinical Results of Ilixadencel in Combination with Checkpoint Inhibitors and Immune Enhancers at ESMO 2018 22 October 2018 Read more
Immunicum AB (publ) Raises SEK 351M in a Directed Issue and a Fully Guaranteed Rights Issue for Continued Clinical Development of Ilixadencel - a New and Innovative Cancer Immunotherapy 16 October 2018 Read more R
Immunicum AB (publ) Gives Information on Trading Halt and Ongoing Negotiations for a Potential Collaboration 1 October 2018 Read more R
Immunicum AB (publ) Announces Upcoming Presentations at Conferences in October 27 September 2018 Read more
Immunicum AB (publ) Announces Appointment of Pawel Kalinski and Inge Marie Svane to Scientific Advisory Board 17 September 2018 Read more
Immunicum AB (publ) to Present Preclinical Data on Ilixadencel in Combination with CPIs and Immune Enhancers at ESMO 2018 Congress 13 August 2018 Read more
Immunicum AB (publ) Announces Protocol Approval by the FDA Enabling the Initiation of Expanded Multi-indication Phase Ib/II Combination Trial 23 July 2018 Read more R
Immunicum AB (publ) Announces Publication of Scientific Review of Ilixadencel Approach in Pharmaceutical Research 18 June 2018 Read more
Immunicum AB (publ) Announces End of Enrollment in Phase I/II GIST Clinical Trial 21 May 2018 Read more R
Immunicum AB (publ) Announces Upcoming Presentations and Attendances at Conferences in May and June 14 May 2018 Read more
Report from the Annual General Meeting of Immunicum AB (publ) on April 25, 2018 25 April 2018 Read more R
Immunicum AB (publ) Provides Update on Ilixadencel Clinical Development Program 3 April 2018 Read more
Immunicum AB: Immunicum AB (publ) Announces ATMP Certificate Granted by EMA to Ilixadencel for Manufacturing Quality and Non-clinical Data 20 March 2018 Read more
Immunicum AB: The Nomination Committee of Immunicum AB (publ) proposes Michael Oredsson as new Chairman of the Board 14 March 2018 Read more R
Immunicum AB: The Nomination Committee of Immunicum AB (publ) proposes Michael Oredsson as new Chairman of the Board 14 March 2018 Read more R
Immunicum AB (publ) Year-End Report (October - December 2017) Corporate Update and Outlook 16 February 2018 Read more R
Immunicum AB (publ) Presents Case Study of One Patient from Phase I/II HCC Trial at Cholangiocarcinoma Foundation Annual Conference 5 February 2018 Read more
Immunicum AB (publ) Announces Upcoming Presentations and Attendances at Conferences in January and February 22 January 2018 Read more
Immunicum AB (publ) Announces Completion of Patient Recruitment for Phase II MERECA Trial 8 January 2018 Read more R
Change in Number of Shares and Votes in Immunicum AB (publ) After Completed Directed Issue 28 December 2018 Read more R
Immunicum AB (publ) Publishes the Outcome in the Share Issues and Raises SEK 351M 13 December 2018 Read more R
Immunicum AB (publ) Publishes Prospectus in Connection with Rights Issue and Directed Issue 23 November 2018 Read more R
Immunicum AB (publ) Announces Collaboration with Merck KGaA, Darmstadt, Germany, and Pfizer to Evaluate Ilixadencel in Combination with Avelumab in Multi-Indication Phase Ib/II Study 16 November 2018 Read more R
Report from Extraordinary General Meeting of Immunicum AB (publ) on 8 November 2018 8 November 2018 Read more R
Immunicum AB (publ) Raises SEK 351M in a Directed Issue and a Fully Guaranteed Rights Issue for Continued Clinical Development of Ilixadencel - a New and Innovative Cancer Immunotherapy 16 October 2018 Read more R
Immunicum AB (publ) Gives Information on Trading Halt and Ongoing Negotiations for a Potential Collaboration 1 October 2018 Read more R
Immunicum AB (publ) Announces Protocol Approval by the FDA Enabling the Initiation of Expanded Multi-indication Phase Ib/II Combination Trial 23 July 2018 Read more R
Immunicum AB (publ) Announces End of Enrollment in Phase I/II GIST Clinical Trial 21 May 2018 Read more R
Report from the Annual General Meeting of Immunicum AB (publ) on April 25, 2018 25 April 2018 Read more R
Immunicum AB: The Nomination Committee of Immunicum AB (publ) proposes Michael Oredsson as new Chairman of the Board 14 March 2018 Read more R
Immunicum AB: The Nomination Committee of Immunicum AB (publ) proposes Michael Oredsson as new Chairman of the Board 14 March 2018 Read more R
Immunicum AB (publ) Year-End Report (October - December 2017) Corporate Update and Outlook 16 February 2018 Read more R
Immunicum AB (publ) Announces Completion of Patient Recruitment for Phase II MERECA Trial 8 January 2018 Read more R
